IL258893A - Cgrp receptor antagonists - Google Patents
Cgrp receptor antagonistsInfo
- Publication number
- IL258893A IL258893A IL258893A IL25889318A IL258893A IL 258893 A IL258893 A IL 258893A IL 258893 A IL258893 A IL 258893A IL 25889318 A IL25889318 A IL 25889318A IL 258893 A IL258893 A IL 258893A
- Authority
- IL
- Israel
- Prior art keywords
- receptor antagonists
- cgrp receptor
- cgrp
- antagonists
- receptor
- Prior art date
Links
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 title 1
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1519195.0A GB201519195D0 (en) | 2015-10-30 | 2015-10-30 | CGRP Receptor Antagonists |
| PCT/IB2016/056518 WO2017072722A1 (en) | 2015-10-30 | 2016-10-28 | Cgrp receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL258893A true IL258893A (en) | 2018-06-28 |
Family
ID=55130447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL258893A IL258893A (en) | 2015-10-30 | 2018-04-24 | Cgrp receptor antagonists |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9802935B2 (enExample) |
| EP (1) | EP3368536B1 (enExample) |
| JP (1) | JP6874013B2 (enExample) |
| CN (1) | CN108431005B (enExample) |
| AR (1) | AR106488A1 (enExample) |
| AU (1) | AU2016344688A1 (enExample) |
| BR (1) | BR112018008419A2 (enExample) |
| CA (1) | CA3002623A1 (enExample) |
| GB (1) | GB201519195D0 (enExample) |
| IL (1) | IL258893A (enExample) |
| SG (1) | SG11201803380RA (enExample) |
| TW (1) | TW201722952A (enExample) |
| WO (1) | WO2017072722A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201908430D0 (en) | 2019-06-12 | 2019-07-24 | Heptares Therapeutics Ltd | Cgrp antagonist compounds |
| GB201908420D0 (en) | 2019-06-12 | 2019-07-24 | Heptares Therapeutics Ltd | Cgrp antagonist compounds |
| GB202016149D0 (en) * | 2020-10-12 | 2020-11-25 | Heptares Therapeutics Ltd | Cyclic apelin receptor agonists |
| FI4274572T3 (fi) * | 2021-01-05 | 2026-03-27 | Zydus Lifesciences Ltd | Uusia autotaksiinin inhibiittoreita |
| CN117999078A (zh) * | 2021-03-02 | 2024-05-07 | Cgrp诊断公司 | 偏头痛的发生的治疗和/或降低 |
| US20250353860A1 (en) * | 2022-04-29 | 2025-11-20 | Brise Pharmaceuticals Co., Ltd. | Piperidine carboxamide azaindane derivative, method for preparing same, and use thereof |
| WO2024046223A1 (zh) * | 2022-08-30 | 2024-03-07 | 熙源安健医药（上海）有限公司 | 吲唑甲酰胺类衍生物及其制备方法和用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2732221B1 (fr) | 1995-03-28 | 1997-04-25 | Oreal | Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue |
| DE59711622D1 (de) | 1996-09-10 | 2004-06-17 | Boehringer Ingelheim Pharma | Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US20030069231A1 (en) | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
| AU742425B2 (en) | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| US6294534B1 (en) | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
| ES2616539T3 (es) * | 2002-06-05 | 2017-06-13 | Bristol-Myers Squibb Company | Antagonistas de receptores de péptidos relacionados con el gen de calcitonina |
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| JP4673294B2 (ja) * | 2003-03-14 | 2011-04-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 二環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質 |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| TW200524601A (en) | 2003-12-05 | 2005-08-01 | Bristol Myers Squibb Co | Heterocyclic anti-migraine agents |
| JP2007524568A (ja) | 2003-12-05 | 2007-08-30 | ブリストル−マイヤーズ スクイブ カンパニー | カルシトニン遺伝子関連ペプチドレセプターアンタゴニスト |
| TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US20050233980A1 (en) | 2004-04-20 | 2005-10-20 | Boehringer Ingelheim International Gmbh | CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine |
| DE102004019492A1 (de) | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| WO2006006490A1 (ja) * | 2004-07-08 | 2006-01-19 | Ono Pharmaceutical Co., Ltd. | スピロ化合物 |
| EP1802637B1 (en) | 2004-10-13 | 2008-10-15 | Merck & Co., Inc. | Cgrp receptor antagonists |
| DE602005027870D1 (de) | 2004-10-14 | 2011-06-16 | Merck Sharp & Dohme | Cgrp-rezeptorantagonisten |
| US7745427B2 (en) | 2004-10-22 | 2010-06-29 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| EP1770091A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| WO2007141285A1 (en) | 2006-06-08 | 2007-12-13 | Boehringer Ingelheim International Gmbh | Treatment of gastrointestinal disorders with cgrp-antagonists |
| EP2225223B1 (de) * | 2007-11-22 | 2017-01-11 | Boehringer Ingelheim International GmbH | Organische verbindungen |
| US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| TW201031665A (en) * | 2009-02-04 | 2010-09-01 | Gruenenthal Gmbh | Substituted indole-compound |
| US8314117B2 (en) | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8481546B2 (en) | 2010-03-30 | 2013-07-09 | Bristol-Myers Squibb Company | CGRP receptor antagonist |
| US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519194D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
-
2015
- 2015-10-30 GB GBGB1519195.0A patent/GB201519195D0/en not_active Ceased
-
2016
- 2016-10-28 EP EP16791444.9A patent/EP3368536B1/en active Active
- 2016-10-28 AU AU2016344688A patent/AU2016344688A1/en not_active Abandoned
- 2016-10-28 AR ARP160103295A patent/AR106488A1/es unknown
- 2016-10-28 BR BR112018008419A patent/BR112018008419A2/pt not_active Application Discontinuation
- 2016-10-28 CN CN201680063997.2A patent/CN108431005B/zh active Active
- 2016-10-28 SG SG11201803380RA patent/SG11201803380RA/en unknown
- 2016-10-28 US US15/336,880 patent/US9802935B2/en active Active
- 2016-10-28 JP JP2018541592A patent/JP6874013B2/ja active Active
- 2016-10-28 WO PCT/IB2016/056518 patent/WO2017072722A1/en not_active Ceased
- 2016-10-28 CA CA3002623A patent/CA3002623A1/en not_active Abandoned
- 2016-10-28 TW TW105135023A patent/TW201722952A/zh unknown
-
2017
- 2017-09-19 US US15/708,424 patent/US10259812B2/en active Active
-
2018
- 2018-04-24 IL IL258893A patent/IL258893A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN108431005B (zh) | 2020-12-25 |
| US20180009808A1 (en) | 2018-01-11 |
| SG11201803380RA (en) | 2018-05-30 |
| US10259812B2 (en) | 2019-04-16 |
| JP2018532789A (ja) | 2018-11-08 |
| EP3368536B1 (en) | 2019-03-06 |
| JP6874013B2 (ja) | 2021-05-19 |
| AU2016344688A1 (en) | 2018-05-17 |
| EP3368536A1 (en) | 2018-09-05 |
| GB201519195D0 (en) | 2015-12-16 |
| CN108431005A (zh) | 2018-08-21 |
| AR106488A1 (es) | 2018-01-17 |
| WO2017072722A1 (en) | 2017-05-04 |
| US20170121331A1 (en) | 2017-05-04 |
| BR112018008419A2 (pt) | 2018-11-06 |
| TW201722952A (zh) | 2017-07-01 |
| US9802935B2 (en) | 2017-10-31 |
| CA3002623A1 (en) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258892B (en) | Calcitonin gene-related peptide receptor antagonists | |
| GB201514875D0 (en) | Receptor | |
| GB201518816D0 (en) | Receptor | |
| SI3515887T1 (sl) | Antagonisti TRPV4 | |
| SG11201803380RA (en) | Cgrp receptor antagonists | |
| IL258737A (en) | Antagonists ep4 | |
| ZA201800452B (en) | Cgrp receptor antagonists | |
| DK3331886T3 (da) | Dopamin-d3-receptorantagonister med en bicyclo-del | |
| DK3212637T3 (da) | Dopamin-d3-receptorantagonistforbindelser | |
| GB201702617D0 (en) | Receptor | |
| IL267686A (en) | Integrin antagonists | |
| IL244356B (en) | Formulations for cgrp receptor antagonists | |
| GB201715008D0 (en) | TRPV2 Antagonists | |
| IL258894A (en) | Cgrp receptor antagonists | |
| EP3865472C0 (en) | THROMBOXANE RECEPTOR ANTAGONISTS | |
| IL252903A0 (en) | cgrp antagonist peptides | |
| GB201702174D0 (en) | Orexin receptor antagonists | |
| GB201707499D0 (en) | Orexin receptor antagonists | |
| GB201507202D0 (en) | Receptor tyosine kinase biomarkers | |
| ZA201807767B (en) | Angiotensin-1-receptor antagonists | |
| PT3464324T (pt) | Antagonistas de recetores da angiotensina-1 | |
| ZA201704249B (en) | Cgrp antagonist peptides | |
| GB201707504D0 (en) | Orexin receptor antagonists | |
| GB201701887D0 (en) | Receptor | |
| GB201700926D0 (en) | Receptor |